肾小管细胞来源外泌体在肾纤维化中的研究进展

doi:10.3760/cma.j.cn441417-20241119-05002

摘要/Abstract

摘要：

慢性肾脏病以肾功能衰竭和肾纤维化进展为特征。肾小管细胞来源外泌体介导的细胞间通讯与肾纤维化有关。本文综述肾小管细胞来源外泌体在缺血性或梗阻性损伤后介导成纤维细胞活化和肾纤维化的作用，以及成为肾纤维化的新兴生物学标志物、干预治疗目标和靶向治疗载体的潜力。

关键词:

肾纤维化, 外泌体, 肾小管细胞, 成纤维细胞, 进展

Abstract:

Chronic kidney disease (CKD) patients are increasing rapidly and placing a heavy burden on medical care. CKD is characterized by progressive loss of kidney function and progression of renal fibrosis, and exosome mediated cellular communication has been implicated in various diseases, including renal fibrosis. However, little is known about how exosomes regulate renal fibrosis. This article mainly introduces the key role of tubule-derived exosomes in mediating fibroblast activation and renal fibrosis after ischemic or obstructive injury, and their potential as emerging biological markers, intervention targets and targeted therapy carriers for renal fibrosis. It also summarizes the existing problems and prospects for clinical application.

Key words:

Renal fibrosis, Exosomes, Renal tubular epithelial cells, Fibroblasts, Progress

李晓童于胜强.

肾小管细胞来源外泌体在肾纤维化中的研究进展 [J]. 国际医药卫生导报, 2025, 31(5): 712-718.

Li Xiaotong, Yu Shengqiang.

Research progress of tubule-derived exosomes in renal fibrosis [J]. International Medicine and Health Guidance News, 2025, 31(5): 712-718.

参考文献

[1] Gewin LS. Renal fibrosis: primacy of the proximal tubule[J]. Matrix Biol, 2018, 68-69:248-262. DOI: 10.1016/j.matbio.2018.02.006.
[2] Jing H, Tang S, Lin S, et al. Adiponectin in renal fibrosis[J]. Aging (Albany NY), 2020, 12(5):4660-4672. DOI: 10.18632/aging.102811.
[3] Nastase MV, Zeng-Brouwers J, Wygrecka M, et al. Targeting renal fibrosis: mechanisms and drug delivery systems[J]. Adv Drug Deliv Rev, 2018, 129:295-307. DOI: 10.1016/j.addr.2017.12.019.
[4] Liu BC, Tang TT, Lv LL, et al. Renal tubule injury: a driving force toward chronic kidney disease[J]. Kidney Int, 2018, 93(3):568-579. DOI: 10.1016/j.kint.2017.09.033.
[5] Yang L, Besschetnova TY, Brooks CR, et al. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury[J]. Nat Med, 2010, 16(5):535-543, 1p following 143. DOI: 10.1038/nm.2144.
[6] Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-β: the master regulator of fibrosis[J]. Nat Rev Nephrol, 2016, 12(6):325-338. DOI: 10.1038/nrneph.2016.48.
[7] Zuo Y, Liu Y. New insights into the role and mechanism of Wnt/β-catenin signalling in kidney fibrosis[J]. Nephrology (Carlton), 2018, 23 Suppl 4:38-43. DOI: 10.1111/nep.13472.
[8] Lv LL, Feng Y, Tang TT, et al. New insight into the role of extracellular vesicles in kidney disease[J]. J Cell Mol Med, 2019, 23(2):731-739. DOI: 10.1111/jcmm.14101.
[9] Ståhl AL, Johansson K, Mossberg M, et al. Exosomes and microvesicles in normal physiology, pathophysiology, and renal diseases[J]. Pediatr Nephrol, 2019, 34(1):11-30. DOI: 10.1007/s00467-017-3816-z.
[10] Karpman D, Ståhl AL, Arvidsson I. Extracellular vesicles in renal disease[J]. Nat Rev Nephrol, 2017, 13(9):545-562. DOI: 10.1038/nrneph.2017.98.
[11] He C, Zheng S, Luo Y, et al. Exosome theranostics: biology and translational medicine[J]. Theranostics, 2018, 8(1):237-255. DOI: 10.7150/thno.21945.
[12] Wortzel I, Dror S, Kenific CM, et al. Exosome-mediated metastasis: communication from a distance[J]. Dev Cell, 2019, 49(3):347-360. DOI: 10.1016/j.devcel.2019.04.011.
[13] Guan H, Peng R, Mao L, et al. Injured tubular epithelial cells activate fibroblasts to promote kidney fibrosis through miR-150-containing exosomes[J]. Exp Cell Res, 2020, 392(2):112007. DOI: 10.1016/j.yexcr.2020.112007.
[14] Liu X, Miao J, Wang C, et al. Tubule-derived exosomes play a central role in fibroblast activation and kidney fibrosis[J]. Kidney Int, 2020, 97(6):1181-1195. DOI: 10.1016/j.kint.2019.11.026.
[15] Miranda KC, Bond DT, McKee M, et al. Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease[J]. Kidney Int, 2010, 78(2):191-199. DOI: 10.1038/ki.2010.106.
[16] Deb A, Gupta S, Mazumder PB. Exosomes: a new horizon in modern medicine[J]. Life Sci, 2021, 264:118623. DOI: 10.1016/j.lfs.2020.118623.
[17] Kim DJ, Kang JM, Park SH, et al. Diabetes aggravates post-ischaemic renal fibrosis through persistent activation of TGF-β1 and Shh signalling[J]. Sci Rep, 2017, 7(1):16782. DOI: 10.1038/s41598-017-16977-z.
[18] Chen S, Zhang M, Li J, et al. β-catenin-controlled tubular cell-derived exosomes play a key role in fibroblast activation via the OPN-CD44 axis[J]. J Extracell Vesicles, 2022, 11(3):e12203. DOI: 10.1002/jev2.12203.
[19] Wen J, Ma Z, Livingston MJ, et al. Decreased secretion and profibrotic activity of tubular exosomes in diabetic kidney disease[J]. Am J Physiol Renal Physiol, 2020, 319(4):F664-F673. DOI: 10.1152/ajprenal.00292.2020.
[20] Zhou X, Zhao S, Li W, et al. Tubular cell-derived exosomal miR-150-5p contributes to renal fibrosis following unilateral ischemia-reperfusion injury by activating fibroblast in vitro and in vivo[J]. Int J Biol Sci, 2021, 17(14):4021-4033. DOI: 10.7150/ijbs.62478.
[21] Croker BA, Kiu H, Nicholson SE. SOCS regulation of the JAK/STAT signalling pathway[J]. Semin Cell Dev Biol, 2008, 19(4):414-422. DOI: 10.1016/j.semcdb.2008. 07.010.
[22] Luan J, Fu J, Wang D, et al. miR-150-based RNA interference attenuates tubulointerstitial fibrosis through the SOCS1/JAK/STAT pathway in vivo and in vitro[J]. Mol Ther Nucleic Acids, 2020, 22:871-884. DOI: 10.1016/j.omtn.2020.10.008.
[23] Recio C, Lazaro I, Oguiza A, et al. Suppressor of cytokine signaling-1 peptidomimetic limits progression of diabetic nephropathy[J]. J Am Soc Nephrol, 2017, 28(2):575-585. DOI: 10.1681/ASN.2016020237.
[24] Zhang W, Li X, Tang Y, et al. miR-155-5p implicates in the pathogenesis of renal fibrosis via targeting SOCS1 and SOCS6[J]. Oxid Med Cell Longev, 2020, 2020:6263921. DOI: 10.1155/2020/6263921.
[25] Tsai YC, Kuo MC, Hung WW, et al. Proximal tubule-derived exosomes contribute to mesangial cell injury in diabetic nephropathy via miR-92a-1-5p transfer[J]. Cell Commun Signal, 2023, 21(1):10. DOI: 10.1186/s12964-022- 00997-y.
[26] Simonson MS. Phenotypic transitions and fibrosis in diabetic nephropathy[J]. Kidney Int, 2007, 71(9):846-854. DOI: 10.1038/sj.ki.5002180.
[27] Jin J, Shi X, Li Y, et al. Reticulocalbin 3 deficiency in alveolar epithelium exacerbated bleomycin-induced pulmonary fibrosis[J]. Am J Respir Cell Mol Biol, 2018, 59(3):320-333. DOI: 10.1165/rcmb.2017-0347OC.
[28] Wang L, Wang HL, Liu TT, et al. TGF-Beta as a master regulator of diabetic nephropathy[J]. Int J Mol Sci, 2021, 22(15):7881. DOI: 10.3390/ijms22157881.
[29] Higgins SP, Tang Y, Higgins CE, et al. TGF-β1/p53 signaling in renal fibrogenesis[J]. Cell Signal, 2018, 43:1-10. DOI: 10.1016/j.cellsig.2017.11.005.
[30] Zhang Z, Xing T, Chen Y, et al. Exosome-mediated miR-200b promotes colorectal cancer proliferation upon TGF-β1 exposure[J]. Biomed Pharmacother, 2018, 106:1135-1143. DOI: 10.1016/j.biopha.2018.07.042.
[31] Zhao S, Li W, Yu W, et al. Exosomal miR-21 from tubular cells contributes to renal fibrosis by activating fibroblasts via targeting PTEN in obstructed kidneys[J]. Theranostics, 2021, 11(18):8660-8673. DOI: 10.7150/thno.62820.
[32] Glowacki F, Savary G, Gnemmi V, et al. Increased circulating miR-21 levels are associated with kidney fibrosis[J]. PLoS One, 2013, 8(2):e58014. DOI: 10.1371/journal.pone.0058014.
[33] Zarjou A, Yang S, Abraham E, et al. Identification of a microRNA signature in renal fibrosis: role of miR-21[J]. Am J Physiol Renal Physiol, 2011, 301(4):F793-F801. DOI: 10.1152/ajprenal.00273.2011.
[34] Yu X, Odenthal M, Fries JW. Exosomes as miRNA carriers: formation-function-future[J]. Int J Mol Sci, 2016, 17(12):2028. DOI: 10.3390/ijms17122028.
[35] Du J, Liang Y, Li J, et al. Gastric cancer cell-derived exosomal microRNA-23a promotes angiogenesis by targeting PTEN[J]. Front Oncol, 2020, 10:326. DOI: 10.3389/fonc.2020.00326.
[36] Xu H, Ling M, Xue J, et al. Exosomal microRNA-21 derived from bronchial epithelial cells is involved in aberrant epithelium-fibroblast cross-talk in COPD induced by cigarette smoking[J]. Theranostics, 2018, 8(19):5419-5433. DOI: 10.7150/thno.27876.
[37] Hu Y, Rao SS, Wang ZX, et al. Exosomes from human umbilical cord blood accelerate cutaneous wound healing through miR-21-3p-mediated promotion of angiogenesis and fibroblast function[J]. Theranostics, 2018, 8(1):169-184. DOI: 10.7150/thno.21234.
[38] Luo Q, Cai Z, Tu J, et al. Total flavonoids from Smilax glabra Roxb blocks epithelial-mesenchymal transition and inhibits renal interstitial fibrosis by targeting miR-21/PTEN signaling[J]. J Cell Biochem, 2019, 120(3):3861-3873. DOI: 10.1002/jcb.27668.
[39] Liu D, Liu F, Li Z, et al. HNRNPA1-mediated exosomal sorting of miR-483-5p out of renal tubular epithelial cells promotes the progression of diabetic nephropathy-induced renal interstitial fibrosis[J]. Cell Death Dis, 2021, 12(3):255. DOI: 10.1038/s41419-021- 03460-x.
[40] Ma N, Xiang Y, Zhang Y, et al. The balance mediated by miRNAs and the heme oxygenase 1 feedback loop contributes to biological effects[J]. J Cell Biochem, 2013, 114(12):2637-2642. DOI: 10.1002/jcb.24631.
[41] Strutz F, Zeisberg M. Renal fibroblasts and myofibroblasts in chronic kidney disease[J]. J Am Soc Nephrol, 2006, 17(11):2992-2998. DOI: 10.1681/ASN.2006050420.
[42] Li H, Zhang L, Wang F, et al. Attenuation of glomerular injury in diabetic mice with tert-butylhydroquinone through nuclear factor erythroid 2-related factor 2-dependent antioxidant gene activation[J]. Am J Nephrol, 2011, 33(4):289-297. DOI: 10.1159/000324694.
[43] Ebadi Z, Moradi N, Kazemi Fard T, et al. Captopril and spironolactone can attenuate diabetic nephropathy in Wistar rats by targeting microRNA-192 and microRNA-29a/b/c[J]. DNA Cell Biol, 2019, 38(10):1134-1142. DOI: 10.1089/dna.2019.4732.
[44] Kelly KJ, Zhang J, Han L, et al. Improved structure and function in autosomal recessive polycystic rat kidneys with renal tubular cell therapy[J]. PLoS One, 2015, 10(7):e0131677. DOI: 10.1371/journal.pone.0131677.
[45] Fakhredini F, Mansouri E, Mard SA, et al. Effects of exosomes derived from kidney tubular cells on diabetic nephropathy in rats[J]. Cell J, 2022, 24(1):28-35. DOI: 10.22074/cellj.2022.7591.
[46] Petrillo F, Iervolino A, Zacchia M, et al. MicroRNAs in renal diseases: a potential novel therapeutic target[J]. Kidney Dis (Basel), 2017, 3(3):111-119. DOI: 10.1159/000481730.